{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:52:50Z","timestamp":1783075970268,"version":"3.54.6"},"reference-count":82,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2010,10,27]],"date-time":"2010-10-27T00:00:00Z","timestamp":1288137600000},"content-version":"vor","delay-in-days":299,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dev Disabil Res Revs"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The review presented here describes the state of the art of pharmacological treatment of aggression in subjects with mental retardation (MR) summing up results for both, children and adults. In general, psychopharmacological treatment of disruptive behavior in individuals with MR is similar to the treatment in subjects without MR. Compared to individuals without MR medication should \u201cstart lower and go slower.\u201d For children and adults results were similar but were obtained by somewhat different medications. There is evidence for the conventional antipsychotic zuclopenthixol having positive effects on disruptive behavior. Most studies described the atypical antipsychotic risperidone to control severe self\u2010injurious behavior and other behavior problems in a variety of diagnoses. Anticonvulsants, antidepressants, and anxiolytic medications are reported as effective as well for the treatment of individuals with disruptive behavior. Aggression\u2010related behavior often gets treated with stimulants or with stimulants combined with atypical neuroleptics. \u00a9 2010 Wiley\u2010Liss, Inc. Dev Disabil Res Rev 2010;16:265\u2013272.<\/jats:p>","DOI":"10.1002\/ddrr.119","type":"journal-article","created":{"date-parts":[[2010,10,27]],"date-time":"2010-10-27T12:50:21Z","timestamp":1288183821000},"page":"265-272","source":"Crossref","is-referenced-by-count":44,"title":["Pharmacotherapy of disruptive behavior in mentally retarded subjects: A review of the current literature"],"prefix":"10.1002","volume":"16","author":[{"given":"Frank","family":"H\u00e4\u00dfler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,10,27]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1352\/0047-6765(2001)039<0259:DBPCTO>2.0.CO;2"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2779(1999)5:4<279::AID-MRDD5>3.0.CO;2-6"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1089\/104454603321666171"},{"key":"e_1_2_5_5_1","first-page":"485","article-title":"The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects","volume":"89","author":"Aman MG","year":"1985","journal-title":"Am J Ment Defic"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.8.1337"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0891-4222(95)00039-9"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/pmj.79.929.139"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.158.2.251"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199308000-00001"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881106075642"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2788.1998.00144.x"},{"key":"e_1_2_5_13_1","first-page":"CD000377","article-title":"Antipsychotic medication for challenging behaviour in people with learning disability","volume":"3","author":"Brylewski J","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2000.10.19"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0405"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0612h"},{"key":"e_1_2_5_17_1","first-page":"544","article-title":"Development of neuropharmacologically based behavior assessments of impulsive aggressive behavior","volume":"3","author":"Coccaro EF","year":"1991","journal-title":"J Neuropsychiatry Clin Neuroscience"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200203000-00004"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000145805.24274.09"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-3101"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2788.2001.00373.x"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0b013e3282ab9952"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.2002.tb00266.x"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ridd.2008.10.010"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G499"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2788.2003.00464.x"},{"key":"e_1_2_5_27_1","unstructured":"FDA Talk Paper.2005. 1 PV 3758 AMP STRATTERA (atomoxetine HCl) description. Available at:www.fda.gov\/medwatch\/SAFETY\/2005\/MAY_PI\/Strattera_PI.pdf"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.4.677"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200004000-00021"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1089\/1044546041649129"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000219832.23849.31"},{"key":"e_1_2_5_32_1","first-page":"29","article-title":"The epidemiology of pervasive developmental disorders","volume":"5","author":"Fombonne E","year":"2003","journal-title":"T.E.N."},{"key":"e_1_2_5_33_1","first-page":"314","article-title":"Clinical evaluation of treatment with fluvoxamine, a selective serotonin reuptake inhibitor in children with autistic disorder","volume":"33","author":"Fukuda T","year":"2001","journal-title":"Brain Dev"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-2093-2"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00585.x"},{"key":"e_1_2_5_36_1","volume-title":"Child and adolescent clinical psychopharmacology","author":"Green WH","year":"2001"},{"key":"e_1_2_5_37_1","first-page":"217","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Guy W","year":"1976"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.105.016535"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1082072"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-7610.2006.01588.x"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000223312.48406.6e"},{"key":"e_1_2_5_42_1","first-page":"426","article-title":"Klinisch\u2010jugendpsychiatrische Erfahrungen mit Ciatyl\u00ae","volume":"62","author":"Heinze H","year":"1967","journal-title":"Med Klin"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1089\/10445460152595559"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ridd.2004.03.004"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.16.541"},{"key":"e_1_2_5_46_1","first-page":"265","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Honigfeld G","year":"1976"},{"key":"e_1_2_5_47_1","first-page":"217","article-title":"Zuclopenthixol decanoate in the management of behavioral disorders in mentally handicapped patients","volume":"5","author":"Izmeth MGA","year":"1988","journal-title":"Pharmatherapeutica"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000088906.24613.76"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1017\/S146114570400481X"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2005.15.325"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1981.tb06212.x"},{"key":"e_1_2_5_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200210000-00003"},{"key":"e_1_2_5_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199305000-00013"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-3955(05)70068-7"},{"key":"e_1_2_5_55_1","doi-asserted-by":"publisher","DOI":"10.1901\/jaba.2003.36-205"},{"key":"e_1_2_5_56_1","first-page":"299","article-title":"Clomipramine treatment for stereotype and related repetitive movement disorders associated with mental retardation","volume":"100","author":"Lewis MH","year":"1995","journal-title":"Am J Psychiatry"},{"key":"e_1_2_5_57_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.166.3.374"},{"key":"e_1_2_5_58_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.1999.9.99"},{"key":"e_1_2_5_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013171"},{"key":"e_1_2_5_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200208000-00010"},{"key":"e_1_2_5_61_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001504-200209000-00003"},{"key":"e_1_2_5_62_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000120024.14101.96"},{"key":"e_1_2_5_63_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.11.1266"},{"key":"e_1_2_5_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01321457"},{"key":"e_1_2_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07059-7"},{"key":"e_1_2_5_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2008.11.017"},{"key":"e_1_2_5_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ridd.2004.07.001"},{"key":"e_1_2_5_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2788.1992.tb00572.x"},{"key":"e_1_2_5_69_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.1997.7.255"},{"key":"e_1_2_5_70_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200209000-00002"},{"key":"e_1_2_5_71_1","doi-asserted-by":"publisher","DOI":"10.1089\/10445460152595595"},{"key":"e_1_2_5_72_1","doi-asserted-by":"publisher","DOI":"10.1089\/104454604773840481"},{"key":"e_1_2_5_73_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2004.14.455"},{"key":"e_1_2_5_74_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-19838"},{"key":"e_1_2_5_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.2000.tb00083.x"},{"key":"e_1_2_5_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/mrdd.20031"},{"key":"e_1_2_5_77_1","article-title":"Amfetamine for attention deficit hyperactivity disorder in people with intellectual disabilities","author":"Thomson A","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_5_78_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0140-6736(08)60072-0","article-title":"Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behavior in patients with intellectual disability: a randomised controlled trial","volume":"371","author":"Tyrer P","year":"2008","journal-title":"Lancet"},{"key":"e_1_2_5_79_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3148.2001.00063.x"},{"key":"e_1_2_5_80_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1995.03950210060011"},{"key":"e_1_2_5_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01550280"},{"key":"e_1_2_5_82_1","doi-asserted-by":"publisher","DOI":"10.1352\/0895-8017(2004)109<310:EORODB>2.0.CO;2"},{"key":"e_1_2_5_83_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.153.5.738a"}],"container-title":["Developmental Disabilities Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fddrr.119","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ddrr.119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T08:35:36Z","timestamp":1694507736000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ddrr.119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1002\/ddrr.119"],"URL":"https:\/\/doi.org\/10.1002\/ddrr.119","archive":["Portico"],"relation":{},"ISSN":["1940-5510","1940-5529"],"issn-type":[{"value":"1940-5510","type":"print"},{"value":"1940-5529","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}